Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
February 03 2022 - 9:00AM
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to
focus on unmet needs and apply proven science and new technology to
revolutionize treatment for patients, starting with eye care, today
announced the appointment of José Trevejo, M.D., Ph.D., as Chief
Medical Officer. Dr. Trevejo brings over 20 years of
experience advancing the clinical development of novel therapeutics
for serious diseases. Dr. Trevejo’s leadership will be highly
valued in the continued advancement of TP-03, the Tarsus pipeline
programs in eye care, dermatology and infectious diseases, and
pipeline expansion opportunities.
“We are delighted to welcome Dr. Trevejo to the Tarsus team at
this key point in the company’s growth, as we complete the second
pivotal clinical trial for our lead investigational product, TP-03,
for the treatment of Demodex blepharitis, and if results are
positive, expect to submit a New Drug Application (NDA) later this
year,” said Bobak Azamian, M.D., Ph.D., President and Chief
Executive Officer of Tarsus Pharmaceuticals. “Dr. Trevejo’s
leadership in drug development and clinical trials will be
instrumental in advancing TP-03 towards FDA approval as well as
expanding our broader pipeline. Additionally, his deep infectious
disease expertise will be particularly impactful in furthering our
novel anti-parasitic platform across several indications, including
our Lyme disease prevention, community malaria reduction, rosacea
and meibomian gland disease treatment programs.”
Before joining Tarsus, Dr. Trevejo served as Chief Development
Officer at Rocket Pharmaceuticals and as CEO of a gene therapy
company, SmartPharm. Prior to SmartPharm, he was the Vice
President, Clinical Development at Cyclerion Therapeutics
(previously a division of Ironwood Pharmaceuticals). Dr. Trevejo
joined Cyclerion from Visterra, where he was a member of the
Executive Team and led the pre-clinical and clinical development of
novel biologics for infectious and rare diseases. Prior to
Visterra, he held clinical development roles at Genentech and
Vertex Pharmaceuticals.
“I am honored to join Tarsus during this exciting time for the
company,” said Dr. Trevejo. “Tarsus has a robust pipeline of
therapies in development, and I look forward to advancing the
clinical programs, contributing to the development of these
innovative and highly anticipated therapies as well as helping to
expand the pipeline.”
Dr. Trevejo completed his clinical training, including an
infectious disease fellowship following an internal medicine
residency at Brigham and Women’s Hospital/Beth-Israel Deaconess
Hospital/Harvard Medical School. He earned his M.D. and Ph.D.
degrees from the Tri-Institutional M.D.-Ph.D. program at
Cornell-Rockefeller-Sloan Kettering in New York City.
About Tarsus Pharmaceuticals, Inc.Tarsus
Pharmaceuticals, Inc. applies proven science and new technology to
revolutionize treatment for patients, starting with eye care. It is
advancing its pipeline to address several diseases with high unmet
need across a range of therapeutic categories, including eye care,
dermatology, and infectious disease prevention. The company is
studying two investigational medicines in clinical trials. Its lead
product candidate, TP-03, is a novel therapeutic being studied in a
second Phase 3 pivotal trial for the treatment of Demodex
blepharitis. TP-03 is also being developed for the treatment of
Meibomian Gland Disease. In addition, Tarsus is developing TP-05,
an oral, non-vaccine therapeutic for the prevention of Lyme
disease, which is currently being studied in a Phase 1b clinical
trial.
Forward Looking Statements Statements in this
press release about future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements.”
These statements include statements regarding Tarsus’ plans for and
the anticipated benefits of its product candidates, including
TP-03, the benefits and value added by the new executive officer,
the timing, objectives and results of the clinical trials and
anticipated regulatory and development milestones, including the
potential commercialization of the Company’s products, and the
quotations of Tarsus’ management. The words, without limitation,
“believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would,” or the negative
of these terms or other similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these or similar identifying
words. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors and are detailed from time to time in the reports Tarsus
files with the Securities and Exchange Commission, including
Tarsus’ Form 10-K for the year ended December 31, 2020 filed on
March 31, 2021 and the most recent Form 10-Q for the quarter ended
September 30, 2021 filed with the SEC on November 10, 2021, which
Tarsus incorporates by reference into this press release, copies of
which are posted on its website and are available from Tarsus
without charge. However, new risk factors and uncertainties may
emerge from time to time, and it is not possible to predict all
risk factors and uncertainties. Accordingly, readers are cautioned
not to place undue reliance on these forward-looking statements.
Any forward-looking statements contained in this press release are
based on the current expectations of Tarsus’ management team and
speak only as of the date hereof, and Tarsus specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Media Contact:SuJin Oh twelvenote(917)
841-5213soh@twelvenote.com
Investor Contact:David
Nakasone Head of
Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2023 to Apr 2024